NICE has provisionally recommended Merck Sharp & Dohme’s Simponi for rheumatoid arthritis alongside other drugs in the TNF inhibitor class. …
Japan’s biggest pharma firm Takeda has denied reports it is negotiating a billion dollar deal to acquire Swiss speciality firm …

The EMA has been hit by a barrage of criticism from the European Parliament over conflicts of interest and the …
Publicis has acquired Dreams Communication, a Chinese agency specialising in healthcare communications. Dreams will become part of Publicis Healthcare Communications …
The NHS Alliance has issued a staunch defence of the principle of GP commissioning – but warned the government to …

The University of Manchester has teamed up with GSK and AstraZeneca to create the Manchester Collaborative Centre for Inflammation Research …
May 12, 2011 [Taoyuan, Taiwan]: SHL has just completed an additional expansion of its Nan Kan 6 facility located in …
Faisal Ahmed has joined Berkshire, UK-based comms agency Life as head of digital. Faisal’s digital pedigree includes being part of …

GPs are being asked not to prescribe NICE-approved drugs in order to cut costs. In the last year more than …
The UK government’s pursuit of Avastin for use in ophthalmology is bad for patients, says the Royal National Institute of …

Roche has submitted its key skin cancer drug vemurafenib to European and American regulators for approval. Vemurafenib (formerly RG7204) has …
AstraZeneca has entered a partnership which intends to speed up the development of targeted treatments for colorectal cancer, a disease …
Medicine regulators are protecting drug company profits over the welfare of patients by withholding trial data. That’s the verdict of …

Novo Nordisk’s new insulin product can eclipse Sanofi’s Lantus within just a few years of its launch, according to Novo’s …
Amsterdam Molecular Therapeutics says it will shortly receive the regulatory verdict on its gene therapy Glybera. Glybera (alipogene tiparvovec) is …

NICE has launched a new online tool that groups its guidance into user-friendly flowcharts to show care pathways. NICE Pathways …
SERVICE INSIGHT Clinical trials are notoriously difficult to manage and often fraught with problems, as they can involve many clinical …
Pfizer has returned the rights to a phase I asthma candidate to Rigel Pharmaceuticals. San Francisco-based Rigel says Pfizer is …
Buckinghamshire-based med comms agency Wave Healthcare has appointed five new members of staff, including a former senior medical liaison manager …

Irish drugmaker Elan has finally found a buyer for its Elan Drug Technologies unit, which has been on and off …